Cargando…
Vascular disrupting agents in clinical development
Growth of human tumours depends on the supply of oxygen and nutrients via the surrounding vasculature. Therefore tumour vasculature is an attractive target for anticancer therapy. Apart from angiogenesis inhibitors that compromise the formation of new blood vessels, a second class of specific antica...
Autores principales: | Hinnen, P, Eskens, F A L M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360146/ https://www.ncbi.nlm.nih.gov/pubmed/17375046 http://dx.doi.org/10.1038/sj.bjc.6603694 |
Ejemplares similares
-
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007) -
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004) -
Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents
por: Rizk, M. L., et al.
Publicado: (2019) -
Pancreatic β cell regeneration induced by clinical and preclinical agents
por: Wang, Kang-Li, et al.
Publicado: (2021) -
The ETS Factor, ETV2: a Master Regulator for Vascular Endothelial Cell Development
por: Oh, Se-Yeong, et al.
Publicado: (2015)